# US 10,478,421 B1 · Sortilin binding compounds, formulations, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,421 B1
- Document ID: US10478421B1
- Status: Granted
- Kind: B1
- Application number: 16/148,839
- Filed: 2018-10-01
- Granted: 2019-11-19
- Earliest claimed: 2016-02-12
- Assignees: University of Florida; University of Rochester
- Applicants: Robert Pleasants Sparks; Wayne Charles Guida; Janet Lindsay DeHoff-Sparks
- Inventors: Robert Pleasants Sparks; Wayne Charles Guida; Janet Lindsay DeHoff-Sparks
- Web page: https://patentgrep.com/patent/US10478421B1

## CPC

- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/381: having five-membered rings
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 333/46: substituted on the ring sulfur atom
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are compounds and formulations thereof that can be capable of binding to sortilin or an analogue thereof. Also provided herein are methods of administering the compounds and formulation provided herein to a subject in need thereof.

## Claims

### Claim 1

A method comprising:
administering an amount of a compound according to Formula 2A
or a pharmaceutical formulation thereof and an amount of compound 541
or a pharmaceutical formulation thereof to a subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject suffers from a disease whose pathology involves a ligand of sortilin or analogue thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the disease is hypercholesteremia or Alzheimer's disease.

### Claim 4 (depends on 2)

The method of claim 2, wherein the ligand of sortilin or analogue thereof is PCSK9, apolipoprotein B100, phosphatidylinositides, anionic phospholipids, anionic phospholipids contained on VLDL, amyloid beta, amyloid precursor protein, neurotensin or analogues of neurotensin, lipoprotein lipase, apolipoprotein AV or apolipoprotein E.

### Claim 5 (depends on 2)

The method of claim 2, wherein the ligand of sortilin or analogue thereof is an apolipoprotein.

### Claim 6 (depends on 2)

The method of claim 2, wherein the ligand of sortilin or analogue thereof is PCSK9.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound having a structure according to Formula 2A or pharmaceutical formulation thereof and compound 541 or pharmaceutical formulation thereof are administered simultaneously.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound having a structure according to Formula 2A or pharmaceutical formulation thereof and compound 541 or pharmaceutical formulation thereof are administered sequentially.

### Claim 9

A method of inhibiting binding of a sortilin ligand to sortilin in a subject, the method comprising:
administering to the subject an effective amount of a compound according to Formula 2A or a pharmaceutical formulation thereof
and an effective amount of compound 541 or a pharmaceutical formulation thereof
wherein the sortilin ligand is selected from the group consisting of: PCSK9, apolipoprotein B100, phosphatidylinositides, anionic phospholipids, anionic phospholipids contained on VLDL, amyloid beta, amyloid precursor protein, neurotensin or analogues of neurotensin, lipoprotein lipase, apolipoprotein AV and apolipoprotein E.

### Claim 10 (depends on 9)

The method of claim 9, wherein the subject suffers from hypercholesteremia or Alzheimer's disease.

### Claim 11 (depends on 9)

The method of claim 9, wherein the subject suffers from hepatic steatosis.

### Claim 12

A pharmaceutical formulation comprising:
an effective amount of a compound having a structure according to Formula 2A
an effective amount of compound 541
and
a pharmaceutically acceptable carrier.
